ArticleInvestigative ophthalmology & visual science2025
Targeting Bcl3/NF-κB p50 Pathway for Neuroinflammation Attenuation and RGCs Protection in Retinal Ischemia/Reperfusion Injury.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Retinal ischemia/reperfusion (IR) injury caused by pathologically high intraocular pressure (ph-IOP) induces excessive inflammation, contributing to retinal ganglion cell (RGC) death in glaucoma. Lowering IOP alone is insufficient, highlighting the need for neuroprotective strategies. Resveratrol (RSV) exhibits anti-inflammatory and neuroprotective effects, but its molecular mechanisms remain unclear. This study aims to evaluate RSV's neuroprotective role and underlying mechanisms in retinal IR injury. Methods: Retinal morphology and RGC survival were assessed via immunofluorescence and hematoxylin and eosin (H&E) staining. Retinal function was evaluated using flash visual evoked potential (F-VEP) and flash electroretinogram (F-ERG). Inflammation and microglial activation were analyzed by quantitative real-time PCR (qRT-PCR) and immunohistochemistry. Pyroptosis and apoptosis were examined using Western blotting, TUNEL staining, and electron microscopy. RNA sequencing, qRT-PCR, and Western blotting identified molecular pathways. Results: RSV significantly protected RGCs and preserved retinal function. It reduced inflammation by inhibiting microglial activation and redistribution. Electron microscopy confirmed its protective effects against apoptosis and pyroptosis. Most importantly, we identified the Bcl3/NF-κB p50 pathway as a key target of RSV. Using the Bcl3-NF-κB p50-specific inhibitor JS-6, we validated this pathway's role in reducing neuroinflammation, pyroptosis, and apoptosis. Conclusions: This study provides insights into RSV's molecular mechanisms and identifies new therapeutic targets for glaucoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.